Dr Patrice Cacoub and colleagues analyzed the barriers to Hepatitis C virus treatment in HIV-Hepatitis C co-infected patients and their evolution between 2004 and 2006.
The team prospectively assessed 380 HIV-Hepatitis C virus co-infected patients in surveys in 2004 and 2006.
|44% deemed Hep C treatment questionable in 2006 vs 53% in 2004|
|Journal of Hepatology|
The researchers found that compared to patients in 2004, those in 2006 had negative Hepatitis C virus RNA more often.
The team found the rate of liver biopsy was similar between the two survey periods.
The research team noted that 24% had had a non-invasive liver damage assessment.
The team found the rate of previous treatment for Hepatitis C virus infection was 48% in the 2006 survey vs 26% in the 2004.
The main reasons for Hepatitis C virus non-treatment have changed.
The team noted that 44% deemed the Hepatitis C virus treatment questionable in 2006 vs 53% in 2004.
Lack of liver biopsy was the reason for non-treatment in 18% in 2006 vs 33% in 2004.
Physicians' conviction of poor patient compliance was a reason for non-treatment in 20% in 2006 vs 30% in 2004.
The team found in both surveys, that Hepatitis C virus treated patients were more often of European origin.
Patients in both surveys had better control of HIV infection, and had a liver damage assessment more often.
Dr Cacoub's team concluded, "The care of HIV-Hepatitis C virus co-infected patients has changed significantly in real life."
"These results underline the importance of continuing efforts to educate physicians and patients in order to increase the access of co-infected patients to Hepatitis C virus treatment."